Monteris Medical launches NeuroBlate SideFire Select and FullFire Select reduced diameter laser mini-probes


Monteris Medical has announced the launch of two new reduced diameter mini-probes for its NeuroBlate System, a minimally invasive robotic laser thermotherapy tool.

Monteris Medical’s new mini-probes have a reduced outer diameter of 2.2mm. Each of the new FDA-cleared probes offers distinct advantages, depending on a surgeon’s particular procedural needs: SideFire Select is a directional laser for contoured ablation of targets while preserving adjacent healthy tissue, whereas the FullFire Select is a diffusing laser designed to provide fast, volumetric ablation in a concentric zone of hyperthermia.


According to the company, NeuroBlate SideFire Select and FullFire Select laser mini-probes can easily be used within a standard MRI bore, and can also be used in conjunction with Monteris Medical’s signature Robotic Probe Driver and Mini-Bolt, as well as other skull fixation devices.


“The new 2.2mm probes retain outstanding target localisation and laser ablation characteristics while having less impact on intervening tissue along the trajectory,” said Adrian W Laxton, assistant professor, Department of Neurosurgery, Wake Forest Baptist Medical Center, USA.


The NeuroBlate System employs a pulsed surgical laser to deliver targeted energy to ablate soft tissue in neurosurgery procedures. With the option of selecting 3.3mm or 2.2mm probes, Monteris offers surgeons the full spectrum of probe choice and added versatility. Each of the probes employs proprietary hyperthermia modulation and a unique sapphire capsule with high laser transparency and robust thermal properties. The probes can also be controlled remotely through Monteris Medical’s Robotic Probe Driver.


“The smaller diameter probes confer several advantages during neurosurgical procedures,” said Alireza Mohammadi, assistant professor of Neurosurgery at a prominent Ohio academic hospital. “The new laser probes have exactly the same efficacy of their larger counterparts, but have a lower profile design and are optimally suited for operating on lesions located in the critical areas of the brain, allowing us to perform surgery on lesions previously thought to be inoperable.”